Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ebola antibody cocktail made available in emergency outbreak

NCT ID NCT03576690

Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access This study
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This program provides emergency access to REGN-EB3, a combination of three antibodies, for people with confirmed Ebola virus disease. It is available to both adults and children in Ebola-affected regions, including pregnant women. The goal is to offer a potential treatment option during outbreaks when no other approved therapies are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
REGN-EB3 (a combination of three antibodies: atoltivimab, maftivimab, and odesivimab)
What this could lead to
If effective, this treatment could help control Ebola virus disease and improve survival rates during outbreaks.
What could go wrong
This is an expanded access program, not a controlled trial, so results may be less reliable. The treatment may not work for all patients and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Males or females in an Ebola endemic region with documented positive polymerase chain reaction (PCR) for Ebola virus infection who are symptomatic * Ability to provide informed consent personally or by a legal representative if the patient is unable to do so, based on local laws and regulations * REGN-EB3 can be administered to pregnant women infected with Zaire ebolavirus, as defined in the protocol * Children of any age will be eligible for enrollment, as defined in the protocol * Neonates born to an infected mother who has not yet cleared the Ebola virus are eligible for enrollment, as defined in the protocol Key Exclusion Criteria: * Negative EBOV diagnostic test result * A patient who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol * Any serious medical condition that, in the opinion of the site investigator, would place the patient at an unreasonable increased risk through participation in this study, including any past or concurrent conditions * Eligible for an ongoing randomized clinical trial with REGN-EB3 NOTE: Other protocol defined inclusion / exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ebola virus disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ebola virus disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.